Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel, Razelle Kurzrock
Molecular Cancer Therapeutics (2015) Vol. 14, Iss. 4, pp. 847-856
Closed Access | Times Cited: 2040

Showing 1-25 of 2040 citing articles:

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Gang Chen, Alexander C. Huang, Wei Zhang, et al.
Nature (2018) Vol. 560, Iss. 7718, pp. 382-386
Open Access | Times Cited: 2315
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman, Shumei Kato, Lyudmila Bazhenova, et al.
Molecular Cancer Therapeutics (2017) Vol. 16, Iss. 11, pp. 2598-2608
Open Access | Times Cited: 1987
CTLA-4 and PD-1 Pathways
Elizabeth I. Buchbinder, Anupam M. Desai
American Journal of Clinical Oncology (2015) Vol. 39, Iss. 1, pp. 98-106
Open Access | Times Cited: 1947
Immune checkpoint inhibitors: recent progress and potential biomarkers
Pramod Darvin, Salman M. Toor, Varun Sasidharan Nair, et al.
Experimental & Molecular Medicine (2018) Vol. 50, Iss. 12, pp. 1-11
Open Access | Times Cited: 1806
Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Narjust Duma, Rafael Santana-Dávila, Julian R. Molina
Mayo Clinic Proceedings (2019) Vol. 94, Iss. 8, pp. 1623-1640
Closed Access | Times Cited: 1696
Molecular therapies and precision medicine for hepatocellular carcinoma
Josep M. Llovet, Robert Montal, Daniela Sia, et al.
Nature Reviews Clinical Oncology (2018) Vol. 15, Iss. 10, pp. 599-616
Open Access | Times Cited: 1624
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Geoffrey T. Gibney, Louis M. Weiner, Michael B. Atkins
The Lancet Oncology (2016) Vol. 17, Iss. 12, pp. e542-e551
Open Access | Times Cited: 1499
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Fred R. Hirsch, Abigail S. McElhinny, Dave Stanforth, et al.
Journal of Thoracic Oncology (2016) Vol. 12, Iss. 2, pp. 208-222
Open Access | Times Cited: 1173
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Howard L. Kaufman, Jeffery S. Russell, Omid Hamid, et al.
The Lancet Oncology (2016) Vol. 17, Iss. 10, pp. 1374-1385
Open Access | Times Cited: 1145
Current state of immunotherapy for glioblastoma
Michael Lim, Yuanxuan Xia, Chetan Bettegowda, et al.
Nature Reviews Clinical Oncology (2018) Vol. 15, Iss. 7, pp. 422-442
Closed Access | Times Cited: 1119
Neuroinflammation and Central Sensitization in Chronic and Widespread Pain
Ru‐Rong Ji, Andrea G. Nackley, Yul Huh, et al.
Anesthesiology (2018) Vol. 129, Iss. 2, pp. 343-366
Open Access | Times Cited: 1052
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Lorenzo Galluzzi, Juliette Humeau, Aitziber Buqué, et al.
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 12, pp. 725-741
Closed Access | Times Cited: 1004
A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging
Leeat Keren, Marc Bossé, Diana M. Marquez, et al.
Cell (2018) Vol. 174, Iss. 6, pp. 1373-1387.e19
Open Access | Times Cited: 902
Targeting neoantigens to augment antitumour immunity
Mark Yarchoan, Burles A. Johnson, Eric R. Lutz, et al.
Nature reviews. Cancer (2017) Vol. 17, Iss. 4, pp. 209-222
Open Access | Times Cited: 880
Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling
Aadel Chaudhuri, Jacob J. Chabon, Alexander F. Lovejoy, et al.
Cancer Discovery (2017) Vol. 7, Iss. 12, pp. 1394-1403
Open Access | Times Cited: 839
Integrative clinical genomics of metastatic cancer
Dan R. Robinson, Yi-Mi Wu, Robert J. Lonigro, et al.
Nature (2017) Vol. 548, Iss. 7667, pp. 297-303
Open Access | Times Cited: 813
The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker
Denis L. Jardim, Aaron M. Goodman, Débora De Melo Gagliato, et al.
Cancer Cell (2020) Vol. 39, Iss. 2, pp. 154-173
Open Access | Times Cited: 812
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
Thomas Powles, Peter H. O’Donnell, Christophe Massard, et al.
JAMA Oncology (2017) Vol. 3, Iss. 9, pp. e172411-e172411
Open Access | Times Cited: 810
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate
Shumei Kato, Aaron M. Goodman, Vighnesh Walavalkar, et al.
Clinical Cancer Research (2017) Vol. 23, Iss. 15, pp. 4242-4250
Open Access | Times Cited: 769
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
Andrew A. Davis, Vaibhav G. Patel
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 758
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
Lisa Derosa, Matthew D. Hellmann, Marco Spaziano, et al.
Annals of Oncology (2018) Vol. 29, Iss. 6, pp. 1437-1444
Open Access | Times Cited: 731
Molecular profiling for precision cancer therapies
Eoghan Ruadh Malone, Marc Oliva, Peter Sabatini, et al.
Genome Medicine (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 706
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Luc Dirix, István Takács, Guy Jérusalem, et al.
Breast Cancer Research and Treatment (2017) Vol. 167, Iss. 3, pp. 671-686
Open Access | Times Cited: 671
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
Sylvia Adams, P. Schmid, H. S. Rugo, et al.
Annals of Oncology (2018) Vol. 30, Iss. 3, pp. 397-404
Open Access | Times Cited: 671
CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
Levi J. Rupp, Kathrin Schumann, Kole T. Roybal, et al.
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 641
Page 1 - Next Page

Scroll to top